文献速递慢阻肺

Zephyr 支气管内活瓣治疗异质性肺气肿的多中心随机对照试验(TRANSFORM)

A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM).
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

TRANSFORM 是首个多中心随机对照试验,评估 Zephyr 支气管内活瓣(EBV)在无侧支通气的异质性肺气肿患者中的疗效与安全性。结果显示 EBV 组 55.4% 达到主要终点,显著高于对照组的 6.5%,且肺功能、呼吸困难、运动耐量和生活质量的改善在 6 个月时维持,气胸为最常见不良事件。

要点

  • EBV 组 3 个月 FEV1 改善≥12% 者占 55.4%,对照组仅 6.5%(P < 0.001)。
  • 6 个月时 EBV 组 FEV1 平均变化 +20.7%,对照组 -8.6%,组间差异显著。
  • 气胸最常见,EBV 组 65 例中 19 例(29.2%)发生。

核心结论

  • 在无侧支通气的过度充气异质性肺气肿患者中,EBV 治疗在肺功能、呼吸困难、运动耐量和生活质量方面带来有临床意义的获益,安全性可接受。

研究设计与样本

  • 前瞻性、多中心、2:1 随机对照试验,比较 EBV 加标准治疗与单纯标准治疗。
  • 主要终点为术后 3 个月 FEV1 较基线改善≥12% 的受试者百分比。

主要发现

  • 3 个月时 EBV 组 55.4%、标准治疗组 6.5% 的受试者 FEV1 改善≥12%(P < 0.001)。
  • 6 个月时 EBV 组 56.3%、标准治疗组 3.2% 维持 FEV1 改善≥12%(P < 0.001)。
  • 6 个月 FEV1 平均变化:EBV 组 +20.7 ± 29.6%,标准治疗组 -8.6 ± 13.0%。
  • 89.8% 的 EBV 受试者目标肺叶体积减少≥350 ml,平均减少 1.09 ± 0.62 L(P < 0.001)。
  • 6 个月组间差异:残气量 -700 ml,6 分钟步行距离 +78.7 m,SGRQ 评分 -6.5 分,mMRC 评分 -0.6 分,BODE 指数 -1.8 分(均 P < 0.05)。

关键数值与推荐

  • 主要终点阈值:FEV1 较基线改善≥12%。
  • 目标肺叶体积减少阈值:≥350 ml。
  • 气胸发生率为 19/65(29.2%)。

临床怎么用

  • 对于无侧支通气的异质性肺气肿过度充气患者,可考虑 EBV 治疗以改善肺功能、呼吸困难、运动耐量和生活质量。
  • 治疗决策需权衡气胸等不良事件风险,气胸是最常见不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Single-center randomized controlled trials of the Zephyr endobronchial valve (EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is the first multicenter study evaluating this treatment approach. OBJECTIVES: To evaluate the efficacy and safety of Zephyr EBVs in patients with heterogeneous emphysema and absence of collateral ventilation. METHODS: This was a prospective, multicenter 2:1 randomized controlled trial of EBVs plus standard of care or standard of care alone (SoC). Primary outcome at 3 months post-procedure was the percentage of subjects with FEV1 improvement from baseline of 12% or greater. Changes in FEV1, residual volume, 6-minute-walk distance, St. George's Respiratory Questionnaire score, and modified Medical Research Council score were assessed at 3 and 6 months, and target lobe volume reduction on chest computed tomography at 3 months. MEASUREMENTS AND MAIN RESULTS: Ninety seven subjects were randomized to EBV (n = 65) or SoC (n = 32). At 3 months, 55.4% of EBV and 6.5% of SoC subjects had an FEV1 improvement of 12% or more (P < 0.001). Improvements were maintained at 6 months: EBV 56.3% versus SoC 3.2% (P < 0.001), with a mean ± SD change in FEV1 at 6 months of 20.7 ± 29.6% and -8.6 ± 13.0%, respectively. A total of 89.8% of EBV subjects had target lobe volume reduction greater than or equal to 350 ml, mean 1.09 ± 0.62 L (P < 0.001). Between-group differences for changes at 6 months were statistically and clinically significant: ΔEBV-SoC for residual volume, -700 ml; 6-minute-walk distance, +78.7 m; St. George's Respiratory Questionnaire score, -6.5 points; modified Medical Research Council dyspnea score, -0.6 points; and BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index, -1.8 points (all P < 0.05). Pneumothorax was the most common adverse event, occurring in 19 of 65 (29.2%) of EBV subjects. CONCLUSIONS: EBV treatment in hyperinflated patients with heterogeneous emphysema without collateral ventilation resulted in clinically meaningful benefits in lung function, dyspnea, exercise tolerance, and quality of life, with an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT02022683).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Kemp SV, Slebos DJ, Kirk A, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017. PMID: 28885054. doi:10.1164/rccm.201707-1327OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。